AI Insight
Mattias Hammarström's thesis investigated whether lower doses of tamoxifen and its active metabolite endoxifen could prevent breast cancer with fewer side effects in healthy women. The research examined the biological effects of these reduced dosages on breast tissue. Results indicate that lower doses of both tamoxifen and endoxifen may maintain therapeutic benefits while reducing adverse effects.
Why it matters
This research could lead to more tolerable preventive treatments for women at high risk of breast cancer, potentially increasing adherence to preventive therapy. The findings support developing personalized dosing strategies that balance cancer prevention effectiveness with quality of life considerations.
In a new thesis, Mattias Hammarström studied whether lower doses of tamoxifen and also its active metabolite endoxifen for direct administration, as a preventive medication could reduce side effects while still affecting breast tissue in healthy women. The findings suggest that lower doses of tamoxifen and a low dose of endoxifen may offer a better balance between biological effects and side effects, potentially contributing to more individualized approaches to breast cancer prevention.
Source: Q&A: Researcher investigates pharmacological approaches to breast cancer prevention